1.41
price up icon9.63%   0.10
after-market Handel nachbörslich: 1.40 -0.01 -0.71%
loading
Schlusskurs vom Vortag:
$1.31
Offen:
$1.5
24-Stunden-Volumen:
48.07M
Relative Volume:
617.64
Marktkapitalisierung:
$6.10M
Einnahmen:
$960.60K
Nettoeinkommen (Verlust:
$-7.10M
KGV:
-0.1865
EPS:
-7.56
Netto-Cashflow:
$-8.00M
1W Leistung:
+7.98%
1M Leistung:
-24.01%
6M Leistung:
-46.71%
1J Leistung:
-41.85%
1-Tages-Spanne:
Value
$1.31
$1.88
1-Wochen-Bereich:
Value
$1.26
$1.88
52-Wochen-Spanne:
Value
$1.26
$14.83

Soligenix Inc Stock (SNGX) Company Profile

Name
Firmenname
Soligenix Inc
Name
Telefon
609-538-8200
Name
Adresse
29 EMMONS DRIVE, PRINCETON
Name
Mitarbeiter
16
Name
Twitter
@Soligenix_Inc
Name
Nächster Verdiensttermin
2024-11-11
Name
Neueste SEC-Einreichungen
Name
SNGX's Discussions on Twitter

Vergleichen Sie SNGX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
SNGX
Soligenix Inc
1.41 6.10M 960.60K -7.10M -8.00M -7.56
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.67 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

Soligenix Inc Stock (SNGX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2020-07-28 Herabstufung Dawson James Buy → Neutral
2018-01-31 Herabstufung H.C. Wainwright Buy → Neutral
2017-08-14 Bestätigt Maxim Group Buy
2017-07-17 Eingeleitet H.C. Wainwright Buy

Soligenix Inc Aktie (SNGX) Neueste Nachrichten

pulisher
Jun 17, 2025

Soligenix Inc. Advances in Treatment for Behçet’s Disease with SGX945 - citybuzz -

Jun 17, 2025
pulisher
Jun 17, 2025

Soligenix (NASDAQ: SNGX) Makes Advancement in Proprietary Treatment for Behçet’s Disease - The Globe and Mail

Jun 17, 2025
pulisher
Jun 16, 2025

Behcet's Disease Market Growth to Accelerate in Forecast Period - openPR.com

Jun 16, 2025
pulisher
Jun 14, 2025

Cutaneous T-cell Lymphoma Market on Track for Major Expansion by 2034, According to DelveInsight | Innate Pharma, Galderma R&D, Kyowa Kirin, Citius Pharma, Soligenix, 4SC AG, oligenix, Ligand Pharma - Barchart.com

Jun 14, 2025
pulisher
Jun 13, 2025

True North Commercial REIT Announces June 2025 Distribution - The Globe and Mail

Jun 13, 2025
pulisher
Jun 12, 2025

Soligenix Inc. (NASDAQ: SNGX) Makes Strides in Rare Disease Treatments with Upcoming Clinical Trial Results - citybuzz -

Jun 12, 2025
pulisher
Jun 12, 2025

Silicon Valley - FinancialContent

Jun 12, 2025
pulisher
Jun 09, 2025

Soligenix (NASDAQ: SNGX) Offers Hope on the Horizon with HyBryte(TM) Treatment Targeting CTCL - Barchart.com

Jun 09, 2025
pulisher
Jun 06, 2025

Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials | SNGX Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Soligenix Highlights Dr. Ellen Kim’s Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials - GlobeNewswire

Jun 06, 2025
pulisher
Jun 04, 2025

Soligenix Inc. (SNGX) Showcases Promising HyBryte Results in CTCL Treatment Through New Podcast - citybuzz -

Jun 04, 2025
pulisher
Jun 04, 2025

Soligenix (NASDAQ: SNGX) Highlights HyBryte Progress in CTCL via New Podcast Featuring Dr. Ellen Kim - Barchart.com

Jun 04, 2025
pulisher
May 27, 2025

Soligenix (NASDAQ: SNGX) Innovative Treatment to Combat Bacterial Infection Fills Urgent Need for Alternatives to Antibiotics - Barchart.com

May 27, 2025
pulisher
May 27, 2025

Vaccine Contract Manufacturing Market Is Booming Worldwide | - openPR.com

May 27, 2025
pulisher
May 27, 2025

Galaxy Digital Inc. Announces Public Offering of Common Stock - The Globe and Mail

May 27, 2025
pulisher
May 23, 2025

Soligenix’s (NASDAQ: SNGX) HyBryte(TM) Delivers Strong Results In Rare Cancer Trial - Barchart.com

May 23, 2025
pulisher
May 23, 2025

Stocks in play: Brookfield Corporation - The Globe and Mail

May 23, 2025
pulisher
May 23, 2025

Soligenix’s (NASDAQ: SNGX) HyBryte(TM) Delivers Strong Results in Rare Cancer Trial - The Globe and Mail

May 23, 2025
pulisher
May 22, 2025

Chemung Financial Corporation Announces Quarterly Dividend - The Globe and Mail

May 22, 2025
pulisher
May 22, 2025

Soligenix’s HyBryte Shows Promise in Rare Cancer Treatment - citybuzz -

May 22, 2025
pulisher
May 20, 2025

Soligenix (NASDAQ: SNGX) Reports Q1 Milestones, Financial Results - The Globe and Mail

May 20, 2025
pulisher
May 20, 2025

/R E P E A T -- Scotiabank to Announce Second Quarter 2025 Results/ - The Globe and Mail

May 20, 2025
pulisher
May 20, 2025

Public market insider selling at Sprott (SII) - The Globe and Mail

May 20, 2025
pulisher
May 19, 2025

Photodynamic Therapy Market Trends Report 2025-2033, Competitive Analysis of Gladerma, Sun Pharma, Biofrontera, Lumibird, Bausch Health, Soligenix, Modulight, and Theralase TechnologiesResearchAndMarkets.com | FinancialContent - FinancialContent

May 19, 2025
pulisher
May 18, 2025

Zacks Small Cap Predicts Reduced Earnings for Soligenix - Defense World

May 18, 2025
pulisher
May 16, 2025

Zacks Research Issues Business Update as Soligenix (NASDAQ: SNGX) Continues Enrollment in Confirmatory Phase 3 HyBryte Trial - The Globe and Mail

May 16, 2025
pulisher
May 16, 2025

Oral Mucositis Drugs Market Set to Witness Significant Growth - openPR.com

May 16, 2025
pulisher
May 15, 2025

SNGX: Enrollment Continues in Confirmatory Phase 3 Trial of HyBryte™ in CTCL… - MSN

May 15, 2025
pulisher
May 15, 2025

Soligenix Reports Q1 2025 Financial Results and Milestones - TipRanks

May 15, 2025
pulisher
May 13, 2025

SNGX: Enrollment Continues in Confirmatory Phase 3 Trial of HyBryte in CTCL - Research Tree

May 13, 2025
pulisher
May 12, 2025

Contrasting Schrödinger (NASDAQ:SDGR) and Soligenix (NASDAQ:SNGX) - Defense World

May 12, 2025
pulisher
May 10, 2025

Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results - Nasdaq

May 10, 2025
pulisher
May 09, 2025

Soligenix Announces Recent Accomplishments And First Quarter 202 - GuruFocus

May 09, 2025
pulisher
May 07, 2025

Soligenix (NASDAQ: SNGX) CEO Highlights Pipeline and Strategy in BioMedWire Podcast Episode - The Globe and Mail

May 07, 2025
pulisher
May 07, 2025

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Christopher Schaber, CEO of Soligenix Inc. - The Manila Times

May 07, 2025
pulisher
May 05, 2025

Geode Capital Management LLC Has $71,000 Stake in Soligenix, Inc. (NASDAQ:SNGX) - Defense World

May 05, 2025
pulisher
May 05, 2025

Soligenix Issues Interim Results For CTCL Treatment Trial 75% Response At 18 Weeks, 3 Patients Achieve Complete Response - FinancialContent

May 05, 2025
pulisher
May 02, 2025

Soligenix (NASDAQ: SNGX) HyBryte(TM) Paves Way for Breakthrough Treatment for Rare Skin Cancer - Barchart.com

May 02, 2025
pulisher
May 02, 2025

Soligenix (SNGX) Projected to Post Quarterly Earnings on Friday - Defense World

May 02, 2025
pulisher
Apr 30, 2025

Soligenix (NASDAQ: SNGX) Moves Forward To Strengthen The Case For HyBryte(TM) - Barchart.com

Apr 30, 2025
pulisher
Apr 30, 2025

Soligenix (NASDAQ: SNGX) Moves Forward to Strengthen the Case for HyBryte(TM) - The Globe and Mail

Apr 30, 2025
pulisher
Apr 25, 2025

U.S. Severe Oral Mucositis Market Projected To Witness - openPR.com

Apr 25, 2025
pulisher
Apr 24, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 24, 2025
pulisher
Apr 24, 2025

Soligenix reports positive results in skin cancer treatment trial By Investing.com - Investing.com India

Apr 24, 2025
pulisher
Apr 24, 2025

Fireside Chat with Christopher Schaber, Chief Executive Officer of Soligenix, Inc. - Yahoo Finance

Apr 24, 2025
pulisher
Apr 24, 2025

Soligenix reports positive results in skin cancer treatment trial - Investing.com Australia

Apr 24, 2025

Finanzdaten der Soligenix Inc-Aktie (SNGX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.74
price up icon 0.27%
$35.88
price down icon 0.50%
$21.20
price down icon 0.45%
$97.62
price down icon 2.98%
$107.48
price up icon 0.95%
biotechnology ONC
$245.16
price up icon 1.13%
Kapitalisierung:     |  Volumen (24h):